Page 63 Manual de Interações medicamentosas no tratamento da dor crónica

Bibliografia

Adrienne A, N. R. (2010). Prevention, Diagnosis, and Management of Serotonin Syndrome. Am Fam
Physician , 81 (9), 1139-1142.
Baxter, K. (2008). Stockley's Drug Interactions (8th edition ed.). Chicago: Pharmaceutical Press.
Berg, J., Tymoczko, J., & Stryer, L. (2002). Biochemistry. New York: WH Freeman.
Blower, P., de Wit, R., Goodin, S., & Aapro, M. (2005). Drug-drug interactions in oncology: Why are they
important and can they be minimized? Crit Rev Oncol Hematol , 55 (2), 117-42.
Brown, C. (2010). Drug-induced Serotonin Syndrome. Retrieved 6 2017, from www.medscape.com:
http://www.medscape.com/viewarticle/733706
Buajordet, I., Ebbesen, J., & Erikssen, J. (2001). Fatal adverse drug events: the paradox of drug treat-
ment. J Intern Med , 250, 327-341.
Company, B.-M. S. (2004). Changes to labeling for Desyrel (trazodone hydrochloride) tablets. Retrieved
may 28, 2017, from FDA: www.fda.gov/medwatch/safety/2004/desyrel_DHCP.pdf.2004
Dickman, A. (2012). Drugs in Palliative Care. UK: Oxford University Press.
Dunkley E, I. G. (2003). The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision
rules for serotonin toxicity . Q J Med , 96, 635-642.
Fanciullo, G., & Washington, T. (2011). Best Practices to Reduce the Risk of Drug-Drug Interactions:
Opportunities for Managed Care. Am J Manag Care , 17, S299-S304.
Gaeta, T., Fiorini, M., & Ender, K. (2002). Potential drug-drug interactions in elderly patients presenting
with syncope. J Emerg Med , 22 (2), 159-162.
Gallagher, Mahony (2008). STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescrip-
tions): application to acutely ill elderly patients and comparison with Beers’ criteria
Age and Ageing, 37 (6), 673–679
Gillman, P. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity . British Jour-
nal of Anaesthesia , 95 (4), 434-441.
HeisKanen, T., & Kalso, E. (2012). Non-analgesic effects of opioids: Interactions between opioids and
other drugs. Current Pharmaceutical Design , 18 (37), 6079-6089.
Johannessen S, L. C. (2010). Antiepileptic Drug Interactions - Principles and Clinical Implications. Current
Neuropharmacology , 8, 254-267.
Juurlink D, M. M. (2003). Drug-drug interactions among elderly patients hospitalized for drug toxicity.
JAMA , 289, 1652-8.
Kaufman, D., Kelly, F., & Rosenberg, L. (2002). Recent patterns of medication use in the ambulatory adult
population of the United States: The Slone survey. JAMA , 287 (3), 337-344.
Kiyotani, K., Mushiroda, T., Imamura, C., & Hosono, N. (2010). Significant Effect of Polymorphisms in
CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients.
Journal of Clinical Oncology , 28, 1287-1293.
Kotlinska- Lemieszek A, K. P. (2015). Clinically significant drug–drug interactions involving opioid anal-
gesics used for pain treatment in patients with cancer: a systematic review . Drug Design, Development
and Therapy , 9, 5255–5267 .
Lees, J., & Chan, A. (2011). Polypharmacy in elderly patients with cancer: clinical implications and ma-
nagement . Lancet Oncol , 12, 1249-57.
Lohr, L. (2009). Drug interactions with newer oral chemotherapy agents. US Pharmacist , 34 (Oncology
Suppl ), 4-8.
Manchikanti L, M. K. (2009). Prevalence of Side Effects of Prolonged Low or Moderate Dose Opioid
Therapy with Concomitant Benzodiazepine and/or Antidepressant Therapy in Chronic Non-Cancer Pain
. Pain Physician , 12, 259-267.

63